Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
Article
PubMed
Google Scholar
Hashibe M, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. J Natl Cancer Inst. 2007;99(10):777–89.
Article
PubMed
Google Scholar
Gillison ML, et al. Epidemiology of human Papillomavirus-positive head and neck Squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–42.
Article
CAS
PubMed
PubMed Central
Google Scholar
Forte T, et al. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control. 2012;23(8):1343–8.
Article
PubMed
Google Scholar
Chaturvedi AK, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9.
Article
PubMed
PubMed Central
Google Scholar
Chaturvedi AK, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–9.
Article
PubMed
Google Scholar
Gillison ML, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693–703.
Article
CAS
PubMed
Google Scholar
Dayyani F, et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.
Article
PubMed
PubMed Central
Google Scholar
Isaac A, et al. Ultrasensitive detection of oncogenic human papillomavirus in oropharyngeal tissue swabs. J Otolaryngol Head Neck Surg. 2017;46(1):5.
Article
PubMed
PubMed Central
Google Scholar
Fakhry C, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.
Article
CAS
PubMed
Google Scholar
Clark J, et al. Correlation of PET-CT nodal SUVmax with p16 positivity in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2015;44:37.
Article
PubMed
PubMed Central
Google Scholar
Ang KK, Sturgis EM. Human Papillomavirus as a marker of the natural history and response to therapy of head and neck Squamous cell carcinoma. Semin Radiat Oncol. 2012;22(2):128–42.
Article
PubMed
Google Scholar
Xu CC, et al. HPV status and second primary tumours in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2013;42:36.
Article
PubMed
PubMed Central
Google Scholar
Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol. 2009;19(2):97–113.
Article
CAS
PubMed
Google Scholar
Sartor MA, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(−) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics. 2011;6(6):777–87.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Kempen PM, et al. Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics. 2014;9(2):194–203.
Article
PubMed
Google Scholar
Holland D, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res. 2008;68(23):9964–72.
Article
CAS
PubMed
Google Scholar
Biron VL, et al. Epigenetic differences between human papillomavirus-positive and -negative oropharyngeal squamous cell carcinomas. J Otolaryngol Head Neck Surg. 2012;41(Suppl 1):S65–70.
PubMed
Google Scholar
Idris S, et al. Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer. J Otolaryngol Head Neck Surg. 2016;45(1):54.
Article
PubMed
PubMed Central
Google Scholar
Lindsay C, Seikaly H, Biron VL. Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets. J Otolaryngol Head Neck Surg. 2017;46(1):9.
Article
PubMed
PubMed Central
Google Scholar
Oxford. Epigenetics - definition of epigenetics in English | Oxford Dictionaries. Oxford Dictionaries | English 2017 [cited 2017 January 6]; Available from: https://en.oxforddictionaries.com/definition/epigenetics.
Fraga MF, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.
Article
CAS
PubMed
Google Scholar
Varambally S, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9.
Article
CAS
PubMed
Google Scholar
Kleer CG, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cao W, et al. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cancer. 2012;118(11):2858–71.
Article
CAS
PubMed
Google Scholar
Chang CJ, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell. 2011;19(1):86–100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Li Z, et al. The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget. 2013;4(12):2532–49.
Article
PubMed
PubMed Central
Google Scholar
Hyland PL, et al. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J Virol. 2011;85(21):10999–1006.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vire E, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871–4.
Article
CAS
PubMed
Google Scholar
Brenner JC, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32(4):417–26.
PubMed
PubMed Central
Google Scholar
Biron VL, et al. Detection of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma using droplet digital polymerase chain reaction. Cancer. 2016;122(10):1544–51.
Article
CAS
PubMed
Google Scholar
Fiskus W, et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res. 2012;18(22):6227–38.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tan J, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21(9):1050–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Crea F, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012;31(3-4):753–61.
Article
CAS
PubMed
Google Scholar
Miranda TB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8(6):1579–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hayden A, et al. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin a analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat. 2011;127(1):109–19.
Article
CAS
PubMed
Google Scholar
Suva ML, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009;69(24):9211–8.
Article
CAS
PubMed
Google Scholar
Chiba T, et al. 3-Deazaneplanocin a is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer. 2012;130(11):2557–67.
Article
CAS
PubMed
Google Scholar
Kemp CD, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res. 2012;18(1):77–90.
Article
CAS
PubMed
Google Scholar
Crea F, et al. Pharmacologic disruption of Polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011;10:40.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114(13):2733–43.
Article
CAS
PubMed
PubMed Central
Google Scholar
Smits M, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One. 2011;6(1):e16282.
Article
CAS
PubMed
PubMed Central
Google Scholar
Krishnamurthy S, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 2010;70(23):9969–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Coulombe RA Jr, Sharma RP, Huggins JW. Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Eur J Drug Metab Pharmacokinet. 1995;20(3):197–202.
Article
CAS
PubMed
Google Scholar
Sato T, et al. Transcriptional selectivity of epigenetic therapy in cancer. Cancer Res. 2017;77(2):470–81.
Article
CAS
PubMed
Google Scholar
Liu TP, et al. In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes. Oncoscience. 2016;3(1):9–20.
PubMed
PubMed Central
Google Scholar
Ding M, et al. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Clin Exp Pharmacol Physiol. 2015;42(5):458–64.
Article
CAS
PubMed
Google Scholar
Adams AK, Wise-Draper TM, Wells SI. Human papillomavirus induced transformation in cervical and head and neck cancers. Cancers (Basel). 2014;6(3):1793–820.
Article
PubMed Central
Google Scholar
Knutson SK, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890–6.
CAS
PubMed
Google Scholar
Parfenov M, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A. 2014;111(43):15544–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lleras RA, et al. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res. 2013;19(19):5444–55.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bartke T, et al. Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell. 2010;143(3):470–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Braiteh F, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008;14(19):6296–301.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics. 2015;7:127.
Article
PubMed
PubMed Central
Google Scholar
Santos NC, et al. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol. 2003;65(7):1035–41.
Article
CAS
PubMed
Google Scholar
Collins SJ, et al. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A. 1978;75(5):2458–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Seidenfeld J. Effects of difluoromethylornithine on proliferation, polyamine content and plating efficiency of cultured human carcinoma cells. Cancer Chemother Pharmacol. 1985;15(3):196–202.
Article
CAS
PubMed
Google Scholar
Carvalho L, Foulkes K, Mickey DD. Effect of DMSO and DFMO on rat prostate tumor growth. Prostate. 1989;15(2):123–33.
Article
CAS
PubMed
Google Scholar
Iwatani M, et al. Dimethyl sulfoxide has an impact on epigenetic profile in mouse embryoid body. Stem Cells. 2006;24(11):2549–56.
Article
CAS
PubMed
Google Scholar
Kita H, et al. Dimethyl sulfoxide induces chemotherapeutic resistance in the treatment of testicular embryonal carcinomas. Oncol Lett. 2015;10(2):661–6.
PubMed
PubMed Central
Google Scholar
Gassmann M, et al. Quantifying western blots: pitfalls of densitometry. Electrophoresis. 2009;30(11):1845–55.
Article
CAS
PubMed
Google Scholar
Alegria-Schaffer A, Lodge A, Vattem K. Performing and optimizing western blots with an emphasis on chemiluminescent detection. Methods Enzymol. 2009;463:573–99.
Article
CAS
PubMed
Google Scholar
Castillo-Aguilera, O., et al. DNA methylation targeting: the DNMT/HMT crosstalk challenge. Biomol Ther. 2017: 7(1). doi: https://doi.org/10.3390/biom7010003.
Kaminskyy VO, et al. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis. 2011;32(10):1450–8.
Article
CAS
PubMed
Google Scholar
Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45(1):23–30.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003;3(3):187–99.
Article
CAS
PubMed
Google Scholar